These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37797781)

  • 21. Recent advances in CRISPR technologies for genome editing.
    Song M; Koo T
    Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR-Cas engineering in food science and sustainable agriculture: recent advancements and applications.
    Aman Mohammadi M; Maximiano MR; Hosseini SM; Franco OL
    Bioprocess Biosyst Eng; 2023 Apr; 46(4):483-497. PubMed ID: 36707422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas based gene editing: marking a new era in medical science.
    Prasad K; George A; Ravi NS; Mohankumar KM
    Mol Biol Rep; 2021 May; 48(5):4879-4895. PubMed ID: 34143395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.
    Zhang D; Li Z; Li JF
    J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
    Aquino-Jarquin G
    Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress of CRISPR-Cas Based Genome Editing in Photosynthetic Microbes.
    Naduthodi MIS; Barbosa MJ; van der Oost J
    Biotechnol J; 2018 Sep; 13(9):e1700591. PubMed ID: 29396999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases.
    Rahman S; Datta M; Kim J; Jan AT
    Semin Cell Dev Biol; 2019 Dec; 96():22-31. PubMed ID: 31102655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Directed Evolution of CRISPR/Cas Systems for Precise Gene Editing.
    Liu R; Liang L; Freed EF; Gill RT
    Trends Biotechnol; 2021 Mar; 39(3):262-273. PubMed ID: 32828556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA-Dependent RNA Targeting by CRISPR-Cas Systems: Characterizations and Applications.
    Gunitseva N; Evteeva M; Borisova A; Patrushev M; Subach F
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas-mediated diagnostics.
    Li L; Shen G; Wu M; Jiang J; Xia Q; Lin P
    Trends Biotechnol; 2022 Nov; 40(11):1326-1345. PubMed ID: 35595574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR technology: new paradigm to target the infectious disease pathogens.
    Bakhrebah MA; Nassar MS; Alsuabeyl MS; Zaher WA; Meo SA
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3448-3452. PubMed ID: 29917197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CRISPR/Cas9 and gene therapy].
    Giono LE
    Medicina (B Aires); 2017; 77(5):405-409. PubMed ID: 29044017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.
    Piergentili R; Del Rio A; Signore F; Umani Ronchi F; Marinelli E; Zaami S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33919194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing.
    Yang L; Chen J
    Trends Biochem Sci; 2020 Oct; 45(10):874-888. PubMed ID: 32616331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR/Cas Genome Editing in Filamentous Fungi.
    Rozhkova AM; Kislitsin VY
    Biochemistry (Mosc); 2021 Jan; 86(Suppl 1):S120-S139. PubMed ID: 33827404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new era of gene editing for the treatment of human diseases.
    Kc M; Steer CJ
    Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research Progress on Application of CRISPR/Cas Genome Editing Technology in Hematological Diseases -Review].
    Xin LY; Liu AF; Zhong SS; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1284-8. PubMed ID: 27531817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Cas9 for treating hereditary diseases.
    Mani I
    Prog Mol Biol Transl Sci; 2021; 181():165-183. PubMed ID: 34127193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.